Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
January 16 2024 - 1:41PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
January, 2024
Commission File Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x Form
40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes
¨ No
x
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED
(Registrant) |
|
|
|
|
Date: January 16, 2024 |
By: |
/s/ K Randhir Singh |
|
|
Name: |
K Randhir Singh |
|
|
Title: |
Company Secretary |
Exhibit 99.1
|
Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
Tel : +91 40
4900 2900
Fax : +91 40 4900
2999
Email : mail@drreddys.com
www.drreddys.com |
January 16, 2024
National Stock Exchange of India Ltd. (Scrip Code:
DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: Disclosure
pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – information on reported
news item
This is in reference
to Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)
regarding a news item published in “Sky News” and available at the link: https://news.sky.com/story/indian-pharma-group-dr-reddys-eyes-swoop-on-nicotinell-13049500
on January 16, 2024, with the heading “Indian pharma group Dr Reddy's eyes swoop on Nicotinell”.
The said news item is about “Dr Reddy's Laboratories,
an Indian pharmaceutical group, is in talks to buy Nicotinell, the anti-smoking aid, from its FTSE-100 parent company”. In this
regard, please note that the Company does not comment on market speculations and there is currently no such event or information which
requires a disclosure under Regulation 30 of the SEBI Listing Regulations.
In compliance with Regulation 30 of the SEBI Listing
Regulations, the Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure
under the said Regulations.
This is for your information.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
/s/ K
Randhir Singh |
|
K Randhir Singh |
|
Company Secretary, Compliance Officer and Head-CSR
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2024 to May 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From May 2023 to May 2024